Mineralys Therapeutics, Inc. (MLYS): Depreciation & Amortization
$59.0K
Year ended 2025-12-31
$39.0K
Trailing 12 months to 2026-06-30
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.0K | +37.2% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $43.0K | n/a | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $0 | n/a | 2025-02-12, From 2023-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | 2025-12-31 | $59.0K | +37.2% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.28M | +55.0% |
| Immunome Inc. (IMNM) | 2025-12-31 | $2.47M | +57.4% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $8.74M | -6.2% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $2.54M | -0.7% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $6.42M | -10.5% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $3.00M | -34.8% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $60.74M | +39.5% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $6.02M | -2.2% |
Compare MLYS, PTGX, IMNM, NRIX side by side · Screen every company in Pharmaceutical Preparations ↗